{
    "nctId": "NCT01588821",
    "briefTitle": "Cabozantinib in Advanced Solid Malignancies",
    "officialTitle": "Phase II Trial of Cabozantinib (XL184) in Patients With Advanced Solid (Non-breast, Non-prostate) Malignancies and Bony Metastases",
    "overallStatus": "COMPLETED",
    "conditions": "Lung Cancer, Solid Tumor (Not Breast or Prostate Cancers)",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 37,
    "primaryOutcomeMeasure": "Number of Participants With Bone Bio-marker Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologic or cytologic diagnosis of a solid tumor (not breast or prostate) that is metastatic and refractory to or progressed following standard therapies\n* Has bony metastases\n* Agree to use medically accepted methods of contraception\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents within 3 weeks of study entry(6 weeks for nitrosoureas/mitomycin C)\n* Received radiation to the thoracic cavity/GI tract (within 3 months of study entry), to bone or brain metastasis (within 14 days) or to any other site within 28 days\n* Received prior treatment with small molecule kinase inhibitor or hormonal therapy within 14 days/5 half-lives\n* Received therapy with another investigational agent within past 28 days\n* Has not recovered from toxicities due to prior therapies\n* Primary brain tumor\n* Active brain metastases or epidural disease\n* Uncontrolled significant intercurrent or recent illness\n* Allergy or hypersensitivity to components of the study treatment formulation",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}